Skip to content
Psychedelic Safety Data

Trials side by side

One table, one row per trial arm, so different doses, control groups, and whole trials line up against each other. Each rate is the share of participants in that arm with at least one event of the given severity, always shown next to the number analysed. The context columns (phase, population, size) are here because they explain why two rates differ.

A caution before reading across rows: dose, setting, and screening aren’t normalized across trials yet, so this isn’t a like-for-like ranking. It shows each arm as its own trial reported it, and makes no claim about whether a compound is safe.

440 trial arms with reported safety data

CompoundTrial · armPhasePopulationAnalysedSerious AEAny non-seriousDeaths
Ketamine

A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health

NCT05604794Clients
Phase 4Depression, Anxiety18060%0/18060%0/18060%0/1806
Ketamine

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104Esketamine Nasal Spray (OP/MA Phase)
Phase 3Depressive Disorder, Treatment-Resistant111019%212/111091%1010/1110<1%8/1110
Ketamine

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287IND: Intranasal Esketamine + Oral AD
Phase 3Treatment-resistant Depression7792%17/77975%587/7790%0/779
Ketamine

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287OP/MA: Intranasal Esketamine + Oral AD
Phase 3Treatment-resistant Depression6036%38/60375%454/603<1%2/603
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868FU: Intranasal Esketamine + Oral AD
Phase 3Depressive Disorder, Treatment-Resistant481<1%3/4813%14/4810%0/481
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855Follow up: All Participants
Phase 4Depressive Disorder, Treatment-Resistant476<1%1/4762%8/4760%0/477
Ketamine

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104Esketamine Nasal Spray (IND Phase)
Phase 3Depressive Disorder, Treatment-Resistant4581%5/45869%318/458<1%1/458
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868OP: Intranasal Esketamine + Oral AD
Phase 3Depressive Disorder, Treatment-Resistant4552%11/45561%279/4550%0/455
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868IND: Intranasal Esketamine + Oral AD
Phase 3Depressive Disorder, Treatment-Resistant4373%13/43770%306/4370%0/437
Ketamine

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287FU: Intranasal Esketamine + Oral AD
Phase 3Treatment-resistant Depression3572%8/3577%24/3570%0/357
Ketamine

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

NCT04338321Quetiapine Extended Release (XR) + Oral AD
Phase 3Depressive Disorder, Major3365%17/33664%216/336<1%1/336
Ketamine

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

NCT04338321Esketamine Nasal Spray + Oral Antidepressant (AD)
Phase 3Depressive Disorder, Major3346%19/33487%289/334<1%1/334
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855DB: Placebo
Phase 4Depressive Disorder, Treatment-Resistant2501%3/25029%73/2500%0/250
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855OL Treatment: Placebo to Esketamine
Phase 4Depressive Disorder, Treatment-Resistant2373%6/23762%147/2370%0/237
Ketamine

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

NCT03113968Ketamine Infusion
Phase 2/Phase 3Treatment Resistant Depression, Electroconvulsive Therapy1953%5/19516%32/1950%0/195
Ketamine

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

NCT04829318Esketamine + Oral AD
Phase 4Depressive Disorder, Major1836%11/18379%145/183<1%1/183
Ketamine

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

NCT03113968Electroconvulsive Therapy (ECT)
Phase 2/Phase 3Treatment Resistant Depression, Electroconvulsive Therapy1702%4/17016%27/1700%0/170
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868MA: Intranasal Esketamine + Oral AD
Phase 3Depressive Disorder, Treatment-Resistant1523%4/15275%114/1520%0/152
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868MA: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant145<1%1/14531%45/1450%0/145
Ketamine

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD)
Phase 3Depressive Disorder, Treatment-Resistant1262%3/12694%118/126<1%1/126
Ketamine

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041Double-blind: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant1262%3/12648%61/1260%0/126
Ketamine

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885Phase 1
Phase 4Depression, Anhedonia1230%0/12319%23/1230%0/123
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855DB: Esketamine 84 mg
Phase 4Depressive Disorder, Treatment-Resistant1212%2/12166%80/1210%0/121
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064DB Phase: Intranasal Esk 84 mg + Oral AD
Phase 3Treatment-resistant Depression1160%0/11679%92/1160%0/116
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064DB Phase: Intranasal Esk 56 mg + Oral AD
Phase 3Treatment-resistant Depression1152%2/11581%93/1150%0/115
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585DB Phase: Intranasal Esk + Oral AD
Phase 3Treatment-resistant Depression115<1%1/11578%90/115<1%1/115
Ketamine

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03097133Esketamine 84 mg + SOC
Phase 3Depressive Disorder, Major1144%5/11486%98/1140%0/114
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064DB Phase: Oral AD + Intranasal Placebo
Phase 3Treatment-resistant Depression1130%0/11357%64/1130%0/113
Ketamine

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192Esketamine 84 mg Plus SOC Antidepressant Treatment
Phase 3Depressive Disorder, Major1134%4/11381%91/1130%0/113
Ketamine

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03097133Placebo + Standard of Care (SOC)
Phase 3Depressive Disorder, Major1135%6/11365%74/1130%0/113
Ketamine

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192Placebo Plus SOC Antidepressant Treatment
Phase 3Depressive Disorder, Major1125%6/11259%66/1120%0/112
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585DB Phase: Oral AD + Intranasal Placebo
Phase 3Treatment-resistant Depression109<1%1/10949%53/1090%0/109
Ketamine

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041Follow-up: Intranasal Esketamine+ Oral AD
Phase 3Depressive Disorder, Treatment-Resistant1062%2/1069%10/1060%0/106
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855DB: Esketamine 56 mg
Phase 4Depressive Disorder, Treatment-Resistant105<1%1/10566%69/1050%0/106
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855OL Treatment: Esketamine 84 mg to Esketamine
Phase 4Depressive Disorder, Treatment-Resistant1050%0/10542%44/1050%0/105
Ketamine

Intravenous Ketamine Plus Neurocognitive Training for Depression

NCT03237286Ketamine
Phase 1/Phase 2Depression1030%0/10399%102/1030%0/103
Ketamine

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041Follow-up: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant1032%2/10313%13/1030%0/103
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855OL Treatment: Esketamine 56 mg to Esketamine
Phase 4Depressive Disorder, Treatment-Resistant993%3/9949%49/990%0/99
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868OP_TEP: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant860%0/8647%40/860%0/86
MDMA

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359Pre-Treatment MDMA-Assisted Therapy
Phase 3PTSD850%0/8560%51/850%0/85
MDMA

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359On Day 0, 1, or 2 MDMA-Assisted Therapy
Phase 3PTSD850%0/8599%84/850%0/85
MDMA

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359Treatment-Emergent Adverse Events MDMA-Assisted Therapy
Phase 3PTSD854%3/8599%84/850%0/85
MDMA

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359Follow-Up MDMA-Assisted Therapy
Phase 3PTSD851%1/8518%15/850%0/85
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB: Placebo
Phase 2Depression801%1/8043%34/800%0/80
Psilocybin

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT0377520025 mg COMP360 Psilocybin
Phase 2Treatment Resistant Depression796%5/7976%60/790%0/79
Psilocybin

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT037752001 mg COMP360 Psilocybin
Phase 2Treatment Resistant Depression791%1/7963%50/790%0/79
Ketamine

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

NCT03156504Ketamine
Phase 4Major Depression, Bipolar I Disorder750%0/754%3/750%0/75
Psilocybin

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT0377520010 mg COMP360 Psilocybin
Phase 2Treatment Resistant Depression758%6/7568%51/750%0/75
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186DB Phase: Intranasal Esketamine + Oral AD (4 Weeks)
Phase 3Depressive Disorder, Treatment-Resistant724%3/7261%44/720%0/72
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129Total
Phase 2Depressive Disorder, Treatment-Resistant707%5/7053%37/700%0/70
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064FU Phase: Oral AD + Intranasal Placebo
Phase 3Treatment-resistant Depression691%1/6910%7/690%0/69
MDMA

Effects of MDMA on Social and Emotional Processing

NCT01849419Single Group
NADrug Addiction650%0/650%0/65not reported
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186DB Phase: Oral AD + Intranasal Placebo (4 Weeks)
Phase 3Depressive Disorder, Treatment-Resistant653%2/6534%22/650%0/65
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868FU: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant640%0/642%1/640%0/64
Ketamine

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

NCT02418195MDD With Suicidal Ideation no Attempt
Phase 2Major Depressive Disorder632%1/6392%58/630%0/63
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819DB: Placebo + Midazolam + SOC
Phase 2Depressive Disorder, Major6314%9/6390%57/630%0/63
Ketamine

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

NCT02418195MDD With Recent Suicide Attempt
Phase 2Major Depressive Disorder628%5/6276%47/620%0/62
Ketamine

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

NCT02418195MDD Without Suicidal Ideation no Attempt
Phase 2Major Depressive Disorder612%1/6198%60/610%0/61
Ketamine

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

NCT02418195Healthy Controls
Phase 2Major Depressive Disorder610%0/612%1/610%0/61
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819FU Phase: Placebo + Midazolam + SOC
Phase 2Depressive Disorder, Major5932%19/5981%48/592%1/59
Psilocybin

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595Low Dose Condition (Group)
Phase 2Depressive Symptoms, Anxiety560%0/5618%10/56not reported
Psilocybin

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595High Dose Condition (Group)
Phase 2Depressive Symptoms, Anxiety560%0/5641%23/56not reported
Ketamine

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692Placebo
Phase 2PTSD, Posttraumatic Stress Disorder550%0/5545%25/550%0/55
Ketamine

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692Low Dose Ketamine
Phase 2PTSD, Posttraumatic Stress Disorder550%0/5576%42/550%0/55
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo (Panel A and B: Period 1)
Phase 2Treatment Resistant Depressive Disorder540%0/5450%27/54not reported
Ketamine

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868MA_TEP: Oral AD + Intranasal Placebo
Phase 3Depressive Disorder, Treatment-Resistant542%1/5469%37/540%0/54
Psilocybin

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT03866174Niacin
Phase 2Depressive Disorder, Major540%0/5459%32/540%0/54
Ketamine

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692High Dose Ketamine
Phase 2PTSD, Posttraumatic Stress Disorder530%0/5372%38/530%0/53
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB FU: Placebo
Phase 2Depression534%2/5313%7/530%0/53
MDMA

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

NCT04077437MDMA-assisted Therapy
Phase 3Posttraumatic Stress Disorder530%0/53100%53/530%0/53
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064FU Phase: Intranasal Esk 84 mg + Oral AD
Phase 3Treatment-resistant Depression524%2/528%4/520%0/52
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585FU Phase: Oral AD + Intranasal Placebo
Phase 3Treatment-resistant Depression520%0/5212%6/520%0/52
Psilocybin

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

NCT05847686Treatment (Psilocybin, Therapy)
Phase 1/Phase 2Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm526%3/5258%30/524%2/52
Ketamine

Intravenous Ketamine Plus Neurocognitive Training for Depression

NCT03237286Saline
Phase 1/Phase 2Depression510%0/5175%38/510%0/51
MDMA

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

NCT04077437Placebo With Therapy
Phase 3Posttraumatic Stress Disorder510%0/5196%49/510%0/51
Psilocybin

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT03866174Psilocybin
Phase 2Depressive Disorder, Major500%0/5086%43/500%0/50
Ketamine

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885TMS and PAT
Phase 4Depression, Anhedonia500%0/506%3/500%0/50
Psilocybin

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293Psilocybin
Phase 2Alcohol Dependence480%0/4877%37/480%0/48
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318Open-Label (OL): Flexible Esketamine
Phase 2Depression482%1/4898%47/480%0/48
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318OL FU: Flexible Esketamine
Phase 2Depression484%2/486%3/480%0/48
Ketamine

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430Ketamine
Phase 2Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)474%2/47100%47/47not reported
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064FU Phase: Intranasal Esk 56 mg + Oral AD
Phase 3Treatment-resistant Depression474%2/4715%7/470%0/47
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine/Esketamine/Open Label Esketamine (Panel A and B)
Phase 2Treatment Resistant Depressive Disorder462%1/4685%39/46not reported
Ketamine

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

NCT02452060Treatment/Placebo
Phase 2/Phase 3Pain, Postoperative Depression460%0/4620%9/460%0/46
MDMA

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

NCT03537014MDMA-assisted Therapy
Phase 3Posttraumatic Stress Disorder460%0/46100%46/460%0/46
Psilocybin

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293Diphenhydramine
Phase 2Alcohol Dependence454%2/4564%29/450%0/45
Ketamine

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

NCT02452060Treatment
Phase 2/Phase 3Pain, Postoperative Depression440%0/4416%7/440%0/44
MDMA

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

NCT03537014Placebo With Therapy
Phase 3Posttraumatic Stress Disorder445%2/44100%44/440%0/44
Psilocybin

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994Psilocybin-assisted Treatment
NANicotine Dependence420%0/4288%37/420%0/42
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 84 mg: Follow up Phase
Phase 2Treatment Resistant Depressive Disorder422%1/4217%7/42not reported
Ketamine

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184Healthy Control
Phase 2Major Depressive Disorder, Healthy Controls420%0/422%1/420%0/42
Ketamine

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699MDD: Ketamine
Phase 1/Phase 2Depression, Mood Disorders410%0/4188%36/410%0/41
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318Double Blind (DB): Esketamine 28 mg
Phase 2Depression412%1/4180%33/410%0/41
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB: Esketamine 56 mg
Phase 2Depression410%0/4195%39/410%0/41
Ketamine

Ketamine in the Treatment of Suicidal Depression

NCT01700829Midazolam
Phase 4Major Depressive Disorder, Suicidal Ideation4010%4/4030%12/400%0/40
Ketamine

Ketamine in the Treatment of Suicidal Depression

NCT01700829Ketamine
Phase 4Major Depressive Disorder, Suicidal Ideation4013%5/4025%10/400%0/40
Psilocybin

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994Nicotine Replacement Therapy (NRT)
NANicotine Dependence403%1/4078%31/400%0/40
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB: Esketamine 84 mg
Phase 2Depression403%1/4098%39/400%0/40
LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064Arm 3- 50 μg MM120
Phase 2Anxiety Generalized403%1/4090%36/400%0/40
LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064Arm 4- 100 μg MM120
Phase 2Anxiety Generalized400%0/4098%39/400%0/40
LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064Arm 5- 200 μg MM120
Phase 2Anxiety Generalized400%0/40100%40/400%0/40
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 56 mg: Follow up Phase
Phase 2Treatment Resistant Depressive Disorder393%1/3926%10/39not reported
LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064Arm 1- Placebo
Phase 2Anxiety Generalized390%0/3956%22/390%0/39
LSD

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064Arm 2- 25 μg MM120
Phase 2Anxiety Generalized390%0/3977%30/390%0/39
Ketamine

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699MDD: Placebo
Phase 1/Phase 2Depression, Mood Disorders380%0/3842%16/380%0/38
Ketamine

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203Ketamine
Phase 2Stress Disorders, Post-Traumatic, PTSD3887%33/380%0/380%0/38
Ketamine

Ketamine in the Treatment of Depression

NCT01558063All Subjects
Phase 2Major Depressive Disorder3811%4/380%0/380%0/38
Ketamine

PET Imaging of mGLuR5 With Drug Challenge

NCT01691092Ketamine
NAMajor Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)383%1/380%0/38not reported
Ketamine

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

NCT04560660Ketamine and Prolonged Exposure (PE)
Phase 2PTSD373%1/3789%33/370%0/37
Ketamine

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

NCT04560660Midazolam and Prolonged Exposure (PE)
Phase 2PTSD363%1/3694%34/360%0/36
Ketamine

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001Double Blind (Day 1-25): Esketamine 84 mg
Phase 2Major Depressive Disorder3511%4/3586%30/35not reported
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585FU Phase: Intranasal Esk + Oral AD
Phase 3Treatment-resistant Depression343%1/3421%7/340%0/34
MDMA

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

NCT03282123MDMA-assisted Psychotherapy
Phase 2PTSD333%1/33100%33/330%0/33
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 56 mg (Panel A and B: Period 2)
Phase 2Treatment Resistant Depressive Disorder320%0/3281%26/32not reported
Ketamine

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203Midazolam
Phase 2Stress Disorders, Post-Traumatic, PTSD31100%31/310%0/310%0/31
Ketamine

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001Double Blind (Day 1-25): Placebo
Phase 2Major Depressive Disorder310%0/3181%25/31not reported
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819DB: Esketamine 56 mg + Placebo + SOC
Phase 2Depressive Disorder, Major3123%7/3197%30/310%0/31
Ketamine

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184MDD: Ketamine
Phase 2Major Depressive Disorder, Healthy Controls310%0/3135%11/310%0/31
Ketamine

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184MDD: Midazolam
Phase 2Major Depressive Disorder, Healthy Controls310%0/3116%5/310%0/31
Psilocybin

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

NCT03429075Psilocybin
Phase 2Depressive Disorder, Major300%0/3087%26/300%0/30
Psilocybin

Psilocybin Cancer Anxiety Study

NCT00957359Psilocybin
EARLY_Phase 1Cancer290%0/293%1/290%0/29
Psilocybin

Psilocybin Cancer Anxiety Study

NCT00957359Niacin
EARLY_Phase 1Cancer290%0/290%0/290%0/29
Ketamine

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280Single Ketamine Infusion Preceded by 5 Midazolam Infusions
Phase 2Treatment-resistant Depression293%1/2928%8/290%0/29
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB FU: Esketamine 56 mg
Phase 2Depression290%0/2910%3/290%0/29
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819DB: Esketamine 28 mg + Placebo + SOC
Phase 2Depressive Disorder, Major2914%4/2990%26/290%0/29
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819FU Phase: Esketamine 28 mg + Placebo + SOC
Phase 2Depressive Disorder, Major2934%10/2972%21/290%0/29
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819FU Phase: Esketamine 56 mg + Placebo + SOC
Phase 2Depressive Disorder, Major2928%8/2966%19/290%0/29
Psilocybin

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

NCT03429075Escitalopram
Phase 2Depressive Disorder, Major290%0/2983%24/290%0/29
Ketamine

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

NCT04592809Ketamine
Phase 3Suicide, Attempted, Suicide and Depression2818%5/28100%28/280%0/28
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo/Esketamine/Open Label Esketamine (Panel A and B)
Phase 2Treatment Resistant Depressive Disorder270%0/2781%22/27not reported
Ketamine

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001Follow Up Phase (Day 26-81): Esketamine 84 mg
Phase 2Major Depressive Disorder274%1/2741%11/27not reported
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB Follow Up (FU): Esketamine 28 mg
Phase 2Depression270%0/2711%3/270%0/27
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318PT Phase: Placebo
Phase 2Depression270%0/2726%7/270%0/27
LSD

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

NCT05200936Arm 2- MM120
Phase 2ADHD, Attention Deficit Disorder270%0/2778%21/270%0/27
Ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003Ketamine
Phase 4Major Depression260%0/26100%26/26not reported
Psilocybin

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994Cross-over to Psilocybin-assisted Treatment
NANicotine Dependence264%1/2696%25/260%0/26
Ketamine

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991Placebo
Phase 4Depression260%0/2669%18/260%0/26
Ketamine

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

NCT03470675Epidural Morphine 3 mg + IV Saline
Phase 4Pain, Postpartum Depression260%0/2654%14/260%0/26
LSD

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

NCT05200936Arm 1- Placebo
Phase 2ADHD, Attention Deficit Disorder260%0/2688%23/260%0/26
Ketamine

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430Midazolam
Phase 2Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)250%0/25100%25/25not reported
Ketamine

Alternative Sedation During Bronchoscopy

NCT01158820Placebo
Phase 4Sedation250%0/250%0/250%0/25
Ketamine

Alternative Sedation During Bronchoscopy

NCT01158820Dexmedetomidine and Ketamine
Phase 4Sedation250%0/250%0/250%0/25
Ketamine

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280Six Ketamine Infusions
Phase 2Treatment-resistant Depression254%1/2568%17/250%0/25
Ketamine

Ketamine for Reduction of Alcoholic Relapse

NCT02649231Placebo+Education
Phase 2Primary Alcohol Use Disorder254%1/2568%17/250%0/25
Ketamine

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991Brexpiprazole
Phase 4Depression250%0/2568%17/250%0/25
Ketamine

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

NCT03470675Epidural Morphine 3 mg + IV Ketamine 0.3 mg/kg
Phase 4Pain, Postpartum Depression250%0/2552%13/250%0/25
Ketamine

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699Healthy Volunteer: Ketamine
Phase 1/Phase 2Depression, Mood Disorders240%0/24100%24/240%0/24
Ketamine

Ketamine for Reduction of Alcoholic Relapse

NCT02649231Ketamine+Psychological Therapy
Phase 2Primary Alcohol Use Disorder240%0/2454%13/240%0/24
Ketamine

Ketamine for Reduction of Alcoholic Relapse

NCT02649231Ketamine+Education
Phase 2Primary Alcohol Use Disorder240%0/2471%17/240%0/24
Psilocybin

Effects of Psilocybin in Major Depressive Disorder

NCT03181529Session #1 Through 1-week Post-session #1 Follow-up
Phase 2Major Depressive Disorder240%0/2438%9/240%0/24
Psilocybin

Effects of Psilocybin in Major Depressive Disorder

NCT03181529Session #2 Through 1-week Post-session #2 Follow-up
Phase 2Major Depressive Disorder240%0/2446%11/240%0/24
Ketamine

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885Ketamine
Phase 4Depression, Anhedonia240%0/2417%4/240%0/24
Ketamine

Rapid Antidepressant Effects of Ketamine in Major Depression

NCT00088699Healthy Volunteer: Placebo
Phase 1/Phase 2Depression, Mood Disorders230%0/2335%8/230%0/23
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo (Panel A and B: Period 2) QIDS >=11 Participants
Phase 2Treatment Resistant Depressive Disorder234%1/2365%15/23not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo (Panel A and Panel B: Period 2)
Phase 2Treatment Resistant Depressive Disorder234%1/2352%12/23not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo/Placebo/Open Label Esketamine (Panel A and B)
Phase 2Treatment Resistant Depressive Disorder230%0/23100%23/23not reported
Ketamine

Ketamine for Reduction of Alcoholic Relapse

NCT02649231Placebo+Psychological Therapy
Phase 2Primary Alcohol Use Disorder239%2/2370%16/230%0/23
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318DB FU: Esketamine 84 mg
Phase 2Depression234%1/2313%3/230%0/23
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819DB: Esketamine 84 mg + Placebo + SOC
Phase 2Depressive Disorder, Major234%1/23100%23/230%0/23
Ketamine

Ketamine for Older Adults Pilot

NCT04504175Acute
Phase 4Treatment Resistant Depression, Refractory Depression230%0/2317%4/230%0/23
Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555Ketamine 0.5mg
Phase 2Treatment Resistant Depression220%0/2264%14/220%0/22
Ketamine

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001Follow Up Phase (Day 26-81): Placebo
Phase 2Major Depressive Disorder2223%5/2227%6/22not reported
MDMA

Effects of Drugs on Responses to Brain and Emotional Processes

NCT04053036Placebo
EARLY_Phase 1Autism Spectrum Disorder, Healthy220%0/220%0/220%0/22
MDMA

Effects of Drugs on Responses to Brain and Emotional Processes

NCT04053036MDMA
EARLY_Phase 1Autism Spectrum Disorder, Healthy220%0/220%0/220%0/22
Ketamine

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

NCT04592809Midazolam
Phase 3Suicide, Attempted, Suicide and Depression2232%7/22100%22/220%0/22
Ketamine

Ketamine + Mindfulness for Depression

NCT05168735Intravenous Ketamine + Mindfulness Exercises
Phase 1/Phase 2Depression, Unipolar220%0/22100%22/220%0/22
Psilocybin

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151COMP360 Psilocybin
Phase 2Post Traumatic Stress Disorder220%0/22100%22/220%0/22
Ketamine

Ketamine Anesthesia in Electroconvulsive Therapy

NCT01367119Ketamine
NADepression210%0/210%0/21not reported
Ketamine

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819FU Phase: Esketamine 84 mg + Placebo + SOC
Phase 2Depressive Disorder, Major2133%7/2167%14/210%0/21
MDMA

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

NCT04030169Experimental: MDMA-assisted Psychotherapy
Phase 2PTSD2110%2/21100%21/210%0/21
Ketamine

Ketamine + Mindfulness for Depression

NCT05168735Intravenous Ketamine + Academic Exercises
Phase 1/Phase 2Depression, Unipolar210%0/21100%21/210%0/21
Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555Ketamine 0.2mg
Phase 2Treatment Resistant Depression205%1/2090%18/200%0/20
Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555Ketamine 1.0mg
Phase 2Treatment Resistant Depression200%0/2085%17/200%0/20
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 56 mg (Panel A and B: Period 1)
Phase 2Treatment Resistant Depressive Disorder200%0/2090%18/20not reported
Psilocybin

Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126Psilocybin Administration
Phase 2Cocaine-Related Disorders200%0/2065%13/200%0/20
Psilocybin

Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126Diphenhydramine Administration
Phase 2Cocaine-Related Disorders200%0/2010%2/200%0/20
Ketamine

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927Ketamine + Naltrexone
Phase 1/Phase 2Major Depressive Disorder, Alcohol Use Disorder200%0/2070%14/200%0/20
Ketamine

Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

NCT02487485Ketamine + Sirolimus
Phase 2Depression200%0/2030%6/200%0/20
Ketamine

Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

NCT02487485Ketamine + Placebo
Phase 2Depression200%0/2030%6/200%0/20
MDMA

Effects of MDMA on Emotional and Social Memories

NCT03050541Healthy Adult Volunteers-Oral MDMA at Memory Encoding
NAHealthy200%0/200%0/20not reported
MDMA

Effects of MDMA on Emotional and Social Memories

NCT03050541Healthy Adult Volunteers-Oral MDMA at Memory Retrievial
NAHealthy200%0/200%0/20not reported
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129Placebo Weekly
Phase 2Depressive Disorder, Treatment-Resistant205%1/2025%5/200%0/20
Ketamine

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

NCT03861988Double Blind Ketamine
Phase 4Major Depressive Disorder, Surgery205%1/2035%7/205%1/20
Ketamine

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

NCT03861988Double Blind Placebo
Phase 4Major Depressive Disorder, Surgery2010%2/2030%6/200%0/20
Ketamine

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147Ketamine
NAMajor Depressive Disorder190%0/19100%19/19not reported
Ketamine

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147Placebo
NAMajor Depressive Disorder190%0/19100%19/19not reported
Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555Midazolam (Active Placebo)
Phase 2Treatment Resistant Depression190%0/1953%10/190%0/19
Ketamine

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927Ketamine + Placebo
Phase 1/Phase 2Major Depressive Disorder, Alcohol Use Disorder190%0/1958%11/190%0/19
Ketamine

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927Placebo (Psychoactive Placebo Midazolam) + Placebo
Phase 1/Phase 2Major Depressive Disorder, Alcohol Use Disorder190%0/1974%14/190%0/19
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005Placebo
Phase 1Major Depressive Disorder190%0/1926%5/190%0/19
Psilocybin

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT0473986525 mg COMP360 Psilocybin
Phase 2Treatment Resistant Depression190%0/1963%12/190%0/19
Ketamine

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782Ketamine: 2 Times Per Week
Phase 2Major Depressive Disorder1811%2/1883%15/18not reported
Ketamine

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593Ketamine and Lithium
Phase 2Depression180%0/1883%15/180%0/18
Ketamine

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555Ketamine 0.1mg
Phase 2Treatment Resistant Depression180%0/1894%17/180%0/18
Psilocybin

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467Group Therapy Plus Psilocybin
Phase 1Distress, Depression1817%3/18100%18/180%0/18
Ketamine

Ketamine Anesthesia in Electroconvulsive Therapy

NCT01367119Methohexital
NADepression170%0/170%0/17not reported
Ketamine

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782Ketamine: 3 Times Per Week
Phase 2Major Depressive Disorder170%0/1776%13/17not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 84 mg (Panel A: Period 2)
Phase 2Treatment Resistant Depressive Disorder170%0/1771%12/17not reported
Ketamine

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928Ketamine
Phase 4Major Depressive Disorder, Anxiety Disorder170%0/1788%15/170%0/17
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318PT Phase: Esketamine 84 mg
Phase 2Depression170%0/1735%6/170%0/17
Ketamine

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887Intranasal Ketamine
Phase 3Suicidal Ideation, Depression170%0/1771%12/170%0/17
Ketamine

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779Linkage
EARLY_Phase 1Alcohol Use Disorder, Severe170%0/1735%6/170%0/17
Ketamine

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782Placebo: 2 Times Per Week
Phase 2Major Depressive Disorder160%0/1656%9/16not reported
Ketamine

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782Placebo: 3 Times Per Week
Phase 2Major Depressive Disorder160%0/1650%8/16not reported
Ketamine

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593Ketamine and Placebo
Phase 2Depression160%0/1675%12/160%0/16
Ketamine

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

NCT01881763Ketamine
Phase 4Unipolar Depression, Bipolar Depression160%0/160%0/160%0/16
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 14 mg (Panel B: Period 2)
Phase 2Treatment Resistant Depressive Disorder160%0/1669%11/16not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 28 mg (Panel A: Period 2)
Phase 2Treatment Resistant Depressive Disorder160%0/1650%8/16not reported
Ketamine

Ketamine for Depression: An MRI Study

NCT02544607Ketamine
Phase 4Depression, Anxious Depression160%0/166%1/160%0/16
Ketamine

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928Midazolam
Phase 4Major Depressive Disorder, Anxiety Disorder160%0/1681%13/160%0/16
Psilocybin

Psilocybin-assisted CBT for Depression

NCT05227612Psilocybin-assisted Cognitive Behavioral Therapy (PACBT)
Phase 1Major Depressive Disorder160%0/1694%15/160%0/16
Ketamine

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566Ketamine Arm
Phase 3Postoperative Depression1613%2/160%0/160%0/16
Ketamine

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566Control Arm
Phase 3Postoperative Depression1631%5/1619%3/166%1/16
MDMA

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00090064MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder1513%2/1587%13/150%0/15
MDMA

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00090064SRRs: MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder150%0/15100%15/150%0/15
Ketamine

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

NCT01881763Methohexital
Phase 4Unipolar Depression, Bipolar Depression150%0/150%0/150%0/15
Ketamine

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT02397889Experimental Ketamine Group
Phase 2/Phase 3Posttraumatic Stress Disorder (PTSD)150%0/15100%15/150%0/15
Ketamine

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT02397889Active Control Midazolam Group
Phase 2/Phase 3Posttraumatic Stress Disorder (PTSD)150%0/15100%15/150%0/15
Ketamine

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

NCT02761330Ketamine +ECT
NADepression, Delirium150%0/150%0/150%0/15
Ketamine

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

NCT02761330Etomidate +ECT
NADepression, Delirium150%0/150%0/150%0/15
Ketamine

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

NCT02761330Ketamine Sham
NADepression, Delirium150%0/150%0/150%0/15
Ayahuasca

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

NCT02914769Placebo
Phase 1/Phase 2Major Depression150%0/1527%4/15not reported
Ketamine

Ketamine for Older Adults Pilot

NCT04504175Continuation
Phase 4Treatment Resistant Depression, Refractory Depression150%0/150%0/150%0/15
Ketamine

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548Intravenous Ketamine
Phase 1/Phase 2Depression, Unipolar150%0/1593%14/150%0/15
Psilocybin

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

NCT04950608Psilocybin- Single Arm
Phase 2Hospice, Psilocybin1567%10/1587%13/1560%9/15
Psilocybin

Frontline Clinician Psilocybin Study

NCT05163496Psilocybin Arm
Phase 3Burnout, Caregiver, Burnout, Professional150%0/150%0/150%0/15
Psilocybin

Frontline Clinician Psilocybin Study

NCT05163496Placebo
Phase 3Burnout, Caregiver, Burnout, Professional150%0/150%0/150%0/15
Ketamine

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945Ketamine IV
NAMajor Depressive Disorder140%0/140%0/140%0/14
Ketamine

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998Single Infusion of Ketamine With Prolonged Exposure
Phase 2Posttraumatic Stress Disorder140%0/140%0/140%0/14
Ketamine

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998Midazolam With Prolonged Exposure
Phase 2Posttraumatic Stress Disorder140%0/140%0/140%0/14
Ayahuasca

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

NCT02914769Ayahuasca
Phase 1/Phase 2Major Depression140%0/1471%10/14not reported
Psilocybin

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483Psilocybin
Phase 1Obsessive-Compulsive Disorder147%1/1486%12/140%0/14
Psilocybin

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483Niacin
Phase 1Obsessive-Compulsive Disorder140%0/1443%6/140%0/14
Psilocybin

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483Psilocybin-Unblinded
Phase 1Obsessive-Compulsive Disorder140%0/1471%10/140%0/14
Ketamine

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

NCT03470675Epidural Saline + IV Saline
Phase 4Pain, Postpartum Depression140%0/1429%4/140%0/14
Ketamine

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779XR Naltrexone
EARLY_Phase 1Alcohol Use Disorder, Severe140%0/1436%5/140%0/14
Ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003Lamotrigine Pre-Treatment
Phase 4Major Depression130%0/1338%5/13not reported
Ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003Placebo Pre-Treatment
Phase 4Major Depression130%0/130%0/13not reported
Ketamine

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926Ketamine
NAMajor Depressive Disorder1315%2/1323%3/13not reported
Ketamine

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926Placebo
NAMajor Depressive Disorder130%0/138%1/13not reported
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Active Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1)
Phase 2Posttraumatic Stress Disorder130%0/1362%8/130%0/13
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610SRRs: Active Dose 1
Phase 2Posttraumatic Stress Disorder130%0/130%0/130%0/13
Ketamine

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

NCT01957410Ketamine IV 0.5mg/kg
Phase 2Major Depressive Disorder130%0/1377%10/13not reported
Ketamine

Ketamine in Adolescents With Treatment-Resistant Depression

NCT02078817Ketamine
Phase 2Major Depressive Disorder130%0/1338%5/130%0/13
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568MDMA-assisted Therapy (125 mg) (Blinded)
Phase 2Anxiety130%0/1385%11/130%0/13
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568MDMA Group Open-label MDMA-assisted Therapy (125 mg)
Phase 2Anxiety130%0/1323%3/130%0/13
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568MDMA-assisted Therapy Group 12-month Follow-up
Phase 2Anxiety1323%3/1323%3/138%1/13
Ketamine

Ketamine for Treatment Resistant Late-Life Depression

NCT02556606Midazolam 0.03 mg/kg
Phase 3Treatment Resistant Depressive Disorder138%1/13100%13/130%0/13
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318Post-Treatment (PT) Phase: Esketamine 28 mg
Phase 2Depression130%0/1346%6/130%0/13
Psilocybin

Persisting Effects of Psilocybin

NCT02971605Psilocybin
Phase 1/Phase 2Healthy130%0/1323%3/130%0/13
Ketamine

Ketamine as an Adjunctive Therapy for Major Depression

NCT03256162Ketamine
Phase 1Major Depressive Episode, Unipolar Depression130%0/130%0/130%0/13
Ketamine

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779IV Ketamine
EARLY_Phase 1Alcohol Use Disorder, Severe130%0/1346%6/130%0/13
MDMA

Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

NCT04784143Two Sessions of MDMA-assisted Therapy
Phase 2PTSD130%0/13100%13/130%0/13
Ketamine

Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD

NCT04889664Ketamine and Written Exposure Therapy
Phase 2PTSD130%0/13100%13/130%0/13
Ketamine

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691Ketamine + RO DBT
Phase 1Treatment Resistant Depression130%0/130%0/130%0/13
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Blinded Full Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder120%0/1267%8/120%0/12
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Open-Label Full Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder120%0/1233%4/120%0/12
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405SRRs: Full Dose
Phase 2Posttraumatic Stress Disorder120%0/12100%12/120%0/12
Ketamine

Ketamine For Suicidal Ideation

NCT01507181Ketamine
Phase 4Suicidal Ideation1242%5/12100%12/12not reported
Ketamine

Ketamine For Suicidal Ideation

NCT01507181Midazolam
Phase 4Suicidal Ideation120%0/12100%12/12not reported
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Open-Label Session: Active Dose 1
Phase 2Posttraumatic Stress Disorder120%0/1242%5/120%0/12
Ketamine

The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures

NCT01969227Ketamine Infusion (5 Then 10 mcg/kg/Min) During Propofol Sedation
NAMechanical Ventilation, Airway Patency120%0/120%0/120%0/12
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo to Esketamine 56mg (Panel A and B: Period 2)
Phase 2Treatment Resistant Depressive Disorder120%0/1292%11/12not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 28 mg: Follow up Phase
Phase 2Treatment Resistant Depressive Disorder128%1/1233%4/12not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 84 mg (Panel A: Period 1)
Phase 2Treatment Resistant Depressive Disorder120%0/1283%10/12not reported
Ketamine

Ketamine for Depression and Suicide Risk

NCT02094898Ketamine Infusion
Phase 2Depression, Suicide1217%2/12100%12/128%1/12
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186Follow-up Phase: Intranasal Esketamine + Oral AD (2 Weeks)
Phase 3Depressive Disorder, Treatment-Resistant120%0/128%1/120%0/12
Ketamine

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010Ketamine Followed by NRX-101
Phase 2Bipolar Depression, Suicidal Ideas120%0/1267%8/120%0/12
Ketamine

Ketamine as an Adjunctive Therapy for Major Depression

NCT03256162Midazolam
Phase 1Major Depressive Episode, Unipolar Depression120%0/120%0/120%0/12
Psilocybin

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

NCT04656301Psilocybin
Phase 2Body Dysmorphic Disorders120%0/1292%11/120%0/12
Psilocybin

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

NCT04932434Psilocybin Therapy
Phase 2Parkinson Disease, Depression120%0/1292%11/120%0/12
Psilocybin

Frontline Clinician Psilocybin Study

NCT05163496Open-label Psilocybin (for Placebo Participants)
Phase 3Burnout, Caregiver, Burnout, Professional120%0/120%0/120%0/12
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Full Dose Group 12 Month Follow-Up
Phase 2Posttraumatic Stress Disorder110%0/110%0/110%0/11
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT0179361012 Month Follow-up: Active Dose 1
Phase 2Posttraumatic Stress Disorder110%0/1118%2/110%0/11
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 28 mg (Panel A: Period 1)
Phase 2Treatment Resistant Depressive Disorder110%0/1173%8/11not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 14 mg (Panel B: Period 1)
Phase 2Treatment Resistant Depressive Disorder110%0/1155%6/11not reported
Ketamine

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

NCT02106325Ketamine
Phase 2Depression119%1/1173%8/110%0/11
Ketamine

Ketamine for Treatment Resistant Late-Life Depression

NCT02556606Ketamine 0.50 mg/kg
Phase 3Treatment Resistant Depressive Disorder110%0/11100%11/110%0/11
Ketamine

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

NCT02918318PT Phase: Esketamine 56 mg
Phase 2Depression110%0/1136%4/110%0/11
Ketamine

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887Placebo
Phase 3Suicidal Ideation, Depression110%0/1136%4/110%0/11
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129MIJ821 0.16 mg/kg Weekly*
Phase 2Depressive Disorder, Treatment-Resistant110%0/1164%7/110%0/11
Ketamine

EEG Characteristics in ECT

NCT04022226Methohexital
EARLY_Phase 1Electroconvulsive Therapy, Direct Current Electroencephalogram110%0/110%0/110%0/11
Ketamine

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706Group A (Ketamine)
Phase 2Depression, Opioid-use Disorder110%0/110%0/110%0/11
Ketamine

Treatment Resistant Depression (Pilot)

NCT01179009Ketamine 100-hour Infusion
NADepressive Disorder, Treatment-Resistant100%0/10100%10/100%0/10
Ketamine

Treatment Resistant Depression (Pilot)

NCT01179009Ketamine 40-minute Infusion
NADepressive Disorder, Treatment-Resistant100%0/10100%10/100%0/10
Psilocybin

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

NCT01534494Psilocybin
Phase 2Alcohol Dependence100%0/1070%7/100%0/10
Ketamine

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

NCT02106325Diphenhydramine
Phase 2Depression100%0/1080%8/100%0/10
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129MIJ821 0.16 mg/kg Every Other Week
Phase 2Depressive Disorder, Treatment-Resistant1010%1/1060%6/100%0/10
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129MIJ821 0.32 mg/kg Weekly
Phase 2Depressive Disorder, Treatment-Resistant100%0/1070%7/100%0/10
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129Ketamine 0.5 mg/kg Weekly
Phase 2Depressive Disorder, Treatment-Resistant100%0/1060%6/100%0/10
Ketamine

Ketamine and Prolonged Exposure in PTSD

NCT03960658Ketamine and Prolonged Exposure
Phase 1/Phase 2Post-traumatic Stress Disorder100%0/1030%3/100%0/10
Ketamine

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706Group B (Placebo)
Phase 2Depression, Opioid-use Disorder100%0/100%0/100%0/10
Ketamine

Ketamine Infusion for Comorbid PTSD and Chronic Pain

NCT04322968Chronic Pain With PTSD+IV Ketamine Infusion
Phase 3PTSD, Chronic Pain100%0/100%0/100%0/10
Ketamine

Ketamine Infusion for Comorbid PTSD and Chronic Pain

NCT04322968Chronic Pain Without PTSD+IV Ketamine Infusion
Phase 3PTSD, Chronic Pain100%0/100%0/100%0/10
Ketamine

Ketamine Infusion for Comorbid PTSD and Chronic Pain

NCT04322968Chronic Pain Without PTSD+IV Ketorolac Infusion
Phase 3PTSD, Chronic Pain100%0/100%0/100%0/10
MDMA

Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

NCT04784143Three Sessions of MDMA-assisted Therapy
Phase 2PTSD100%0/10100%10/100%0/10
MDMA

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938Full Dose MDMA-assisted Therapy (125 mg Stage 1)
Phase 2Posttraumatic Stress Disorder922%2/989%8/90%0/9
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1)
Phase 2Posttraumatic Stress Disorder911%1/967%6/90%0/9
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Open-Label Session: Active Dose 2
Phase 2Posttraumatic Stress Disorder911%1/933%3/90%0/9
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT0179361012 Month Follow-up: Active Dose 2
Phase 2Posttraumatic Stress Disorder911%1/911%1/90%0/9
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610SRRs: Active Dose 2
Phase 2Posttraumatic Stress Disorder90%0/90%0/90%0/9
Ketamine

Ketamine for Suicidality in Bipolar Depression

NCT01944293Midazolam
Phase 1/Phase 2Bipolar Disorder, Major Depressive Episode90%0/90%0/90%0/9
Ketamine

Ketamine and Nitroprusside for Depression

NCT03102736Nitroprusside and Ketamine
Phase 2Depression90%0/944%4/90%0/9
Ketamine

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129MIJ821 0.32 mg/kg Every Other Week
Phase 2Depressive Disorder, Treatment-Resistant933%3/967%6/90%0/9
MDMA

Effect of Stimulant Drugs on Social Perception

NCT03790618Placebo
Phase 1Healthy, MDMA ('Ecstasy')90%0/90%0/90%0/9
MDMA

Effect of Stimulant Drugs on Social Perception

NCT03790618Low Dose MDMA
Phase 1Healthy, MDMA ('Ecstasy')90%0/90%0/90%0/9
MDMA

Effect of Stimulant Drugs on Social Perception

NCT03790618High Dose MDMA
Phase 1Healthy, MDMA ('Ecstasy')90%0/90%0/90%0/9
MDMA

Effect of Stimulant Drugs on Social Perception

NCT03790618Methamphetamine
Phase 1Healthy, MDMA ('Ecstasy')90%0/90%0/90%0/9
Ketamine

Ketamine Treatment Effects on Synaptic Plasticity in Depression

NCT04091971Depressed Adults With Current MDD
Phase 4Major Depressive Disorder90%0/956%5/90%0/9
Ketamine

Ketamine Infusion for Comorbid PTSD and Chronic Pain

NCT04322968Chronic Pain With PTSD+IV Ketorolac Infusion
Phase 3PTSD, Chronic Pain90%0/90%0/90%0/9
Psilocybin

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225Psilocybin
Phase 1Perception Disturbance, Visual Suppression90%0/967%6/90%0/9
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005MAD Cohort 2
Phase 1Major Depressive Disorder90%0/922%2/90%0/9
Psilocybin

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT05399498Experimental: Psilocybin
Phase 2Borderline Personality Disorder, Major Depressive Disorder911%1/978%7/90%0/9
MDMA

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00090064Placebo With Therapy
Phase 2Posttraumatic Stress Disorder80%0/8100%8/80%0/8
MDMA

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00090064SRRs: Placebo With Therapy
Phase 2Posttraumatic Stress Disorder80%0/8100%8/80%0/8
Ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003Placebo
Phase 4Major Depression80%0/863%5/8not reported
LSD

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

NCT00920387Full Dose LSD (200 mcg Stage 1)
Phase 2Anxiety813%1/8100%8/813%1/8
Ketamine

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649Placebo
Phase 4Major Depressive Disorder813%1/838%3/80%0/8
Ketamine

NMDA Antagonists in Bipolar Depression

NCT01833897Ketamine and DCS Treatment
Phase 4Bipolar Disorder80%0/850%4/8not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo to Esketamine 28mg (Panel A: Period 2)
Phase 2Treatment Resistant Depressive Disorder80%0/850%4/8not reported
Ketamine

Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects

NCT02669043Ketamine
NADepression80%0/80%0/80%0/8
Ketamine

Ketamine to Improve Recovery After Cesarean Delivery - Part 1

NCT04037085Ketamine
Phase 2Obstetric Pain, Postpartum Depression80%0/888%7/80%0/8
Ketamine

Ketamine to Prevent PPD After Cesarean

NCT04227704Ketamine SC
Phase 3Postpartum Depression80%0/875%6/80%0/8
Ketamine

Ketamine to Prevent PPD After Cesarean

NCT04227704Ketamine IVI
Phase 3Postpartum Depression80%0/875%6/80%0/8
Psilocybin

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225Niacin
Phase 1Perception Disturbance, Visual Suppression80%0/863%5/80%0/8
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Blinded Low Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder714%1/786%6/70%0/7
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Blinded Medium Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder70%0/757%4/70%0/7
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Medium Dose Group 12 Month Follow-Up
Phase 2Posttraumatic Stress Disorder714%1/70%0/70%0/7
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405SRRS: Low Dose
Phase 2Posttraumatic Stress Disorder70%0/7100%7/70%0/7
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405SRRs: Medium Dose
Phase 2Posttraumatic Stress Disorder70%0/7100%7/70%0/7
Ketamine

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990Suicidal, Depression With Ketamine
NADepression, Suicidal Ideation70%0/714%1/7not reported
Ketamine

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990Suicidal, Depression With Saline
NADepression, Suicidal Ideation70%0/70%0/7not reported
Ketamine

Ketamine for Suicidality in Bipolar Depression

NCT01944293Ketamine
Phase 1/Phase 2Bipolar Disorder, Major Depressive Episode757%4/70%0/70%0/7
Ketamine

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377Ketamine Infusions
NATreatment Resistant Depression, Major Depressive Disorder70%0/714%1/70%0/7
Ketamine

Ketamine and Nitroprusside for Depression

NCT03102736Placebo and Ketamine
Phase 2Depression70%0/7100%7/70%0/7
Ketamine

Ketamine to Prevent PPD After Cesarean

NCT04227704Control
Phase 3Postpartum Depression70%0/7100%7/70%0/7
Ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003Riluzole Group
Phase 4Major Depression60%0/6100%6/6not reported
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Open-Label Low Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder617%1/6100%6/60%0/6
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Open-Label Medium Dose MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder60%0/667%4/60%0/6
MDMA

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405Low Dose Group 12 Month Follow-Up
Phase 2Posttraumatic Stress Disorder617%1/60%0/60%0/6
Ketamine

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649Ketamine
Phase 4Major Depressive Disorder60%0/633%2/60%0/6
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1)
Phase 2Posttraumatic Stress Disorder60%0/617%1/60%0/6
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610SRRs: Comparator
Phase 2Posttraumatic Stress Disorder60%0/683%5/60%0/6
Ketamine

Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms

NCT02422303Ketamine Group
NADepression, Major Depressive Disorder60%0/60%0/6not reported
Ketamine

Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms

NCT02422303No Ketamine Group
NADepression, Major Depressive Disorder60%0/60%0/6not reported
MDMA

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

NCT02876172PTSD Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)
Phase 1/Phase 2Posttraumatic Stress Disorder60%0/6100%6/60%0/6
MDMA

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

NCT02876172CSO Patients Open-label CBCT and MDMA-assisted Therapy (up to 2 Months Post Last Experimental Dose)
Phase 1/Phase 2Posttraumatic Stress Disorder60%0/6100%6/60%0/6
MDMA

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

NCT02876172PTSD Patients at 6-month Follow-up
Phase 1/Phase 2Posttraumatic Stress Disorder60%0/633%2/60%0/6
MDMA

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

NCT02876172CSO Patients at 6-month Follow-up
Phase 1/Phase 2Posttraumatic Stress Disorder60%0/633%2/60%0/6
Ketamine

The UTHealth Ketamine Project

NCT02882711Ketamine
Phase 2Treatment Resistant Depression, Major Depressive Disorder617%1/617%1/60%0/6
Ketamine

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453Midazolam Infusion-Blinded
Phase 2Adolescent Suicide, Adolescent Depression650%3/683%5/60%0/6
Ketamine

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453Ketamine Infusion-Unblinded
Phase 2Adolescent Suicide, Adolescent Depression60%0/6100%6/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 1
Phase 1Major Depressive Disorder60%0/617%1/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 2
Phase 1Major Depressive Disorder60%0/60%0/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 3
Phase 1Major Depressive Disorder60%0/617%1/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 4
Phase 1Major Depressive Disorder60%0/617%1/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 5
Phase 1Major Depressive Disorder60%0/617%1/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005SAD Cohort 6
Phase 1Major Depressive Disorder60%0/633%2/60%0/6
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005MAD Cohort 1
Phase 1Major Depressive Disorder60%0/617%1/60%0/6
MDMA

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938Active Placebo MDMA-assisted Therapy (25 mg Stage 1)
Phase 2Posttraumatic Stress Disorder50%0/560%3/50%0/5
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740Blinded Full Dose MDMA-assisted Therapy (125 mg) (Stage 1)
Phase 2Posttraumatic Stress Disorder (PTSD)50%0/580%4/50%0/5
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT0168974012 Month Follow-Up: Blinded Full Dose
Phase 2Posttraumatic Stress Disorder (PTSD)50%0/520%1/50%0/5
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740SRRs: Full Dose
Phase 2Posttraumatic Stress Disorder (PTSD)50%0/5100%5/50%0/5
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610Crossover Open-Label Sessions: Comparator Dose
Phase 2Posttraumatic Stress Disorder50%0/560%3/50%0/5
MDMA

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT0179361012 Month Follow-up: Comparator Dose
Phase 2Posttraumatic Stress Disorder50%0/520%1/50%0/5
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo to Esketamine 14mg (Panel B: Period 2)
Phase 2Treatment Resistant Depressive Disorder50%0/5100%5/5not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo to Esketamine 84 mg (Panel A: Period 2)
Phase 2Treatment Resistant Depressive Disorder50%0/5100%5/5not reported
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568Placebo With Therapy (Blinded)
Phase 2Anxiety50%0/540%2/50%0/5
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg)
Phase 2Anxiety50%0/580%4/50%0/5
MDMA

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568Placebo With Therapy Group 12-month Follow-up
Phase 2Anxiety50%0/540%2/50%0/5
Ketamine

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377Midazolam
NATreatment Resistant Depression, Major Depressive Disorder50%0/50%0/50%0/5
Ketamine

Ketamine for Treatment Resistant Late-Life Depression

NCT02556606Ketamine 0.25 mg/kg
Phase 3Treatment Resistant Depressive Disorder50%0/5100%5/50%0/5
Ketamine

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

NCT02661061Ketamine
Phase 1Depression, Relapse50%0/520%1/50%0/5
Ketamine

Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients

NCT02935595Ketamine
Phase 2Treatment Resistant Depression50%0/520%1/50%0/5
Ketamine

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010Ketamine Followed by Lurasidone
Phase 2Bipolar Depression, Suicidal Ideas50%0/560%3/50%0/5
Ketamine

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

NCT03861988Open Label Ketamine
Phase 4Major Depressive Disorder, Surgery50%0/520%1/50%0/5
Ketamine

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453Ketamine Infusion-Blinded
Phase 2Adolescent Suicide, Adolescent Depression540%2/5100%5/50%0/5
Psilocybin

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

NCT05128162Open Label Dosing Arm (15mg and 25mg)
Phase 2Fibromyalgia50%0/580%4/50%0/5
Ketamine

KAP for Depression in Abstinent Opioid Users

NCT05193318Ketamine-assisted Psychotherapy
Phase 2Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission50%0/560%3/50%0/5
MDMA

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938Full Dose MDMA-assisted Therapy (125 mg Stage 2)
Phase 2Posttraumatic Stress Disorder40%0/450%2/40%0/4
LSD

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

NCT00920387Active Placebo LSD (20 mcg Stage 1)
Phase 2Anxiety425%1/4100%4/40%0/4
MDMA

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

NCT01958593MDMA-assisted Therapy (Stage 1)
Phase 2Posttraumatic Stress Disorder40%0/4100%4/40%0/4
MDMA

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

NCT01958593SRRs: MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder40%0/4100%4/40%0/4
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Esketamine 14 mg: Follow up Phase
Phase 2Treatment Resistant Depressive Disorder40%0/425%1/4not reported
MDMA

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

NCT02008396Group 1: MDMA-assisted Therapy 75mg/100mg
Phase 2Social Anxiety in Autistic Adults40%0/425%1/40%0/4
MDMA

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

NCT02008396Group 2: MDMA-assisted Therapy 100mg/125mg
Phase 2Social Anxiety in Autistic Adults40%0/4100%4/40%0/4
MDMA

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

NCT02008396Inactive Placebo With Psychotherapy (Stage 1)
Phase 2Social Anxiety in Autistic Adults40%0/425%1/40%0/4
Ketamine

Ketamine for Treatment Resistant Late-Life Depression

NCT02556606Ketamine 0.10 mg/kg
Phase 3Treatment Resistant Depressive Disorder40%0/4100%4/40%0/4
Ketamine

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

NCT02661061Midazolam
Phase 1Depression, Relapse40%0/425%1/40%0/4
Ketamine

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010Saline Followed by NRX-101
Phase 2Bipolar Depression, Suicidal Ideas40%0/4100%4/40%0/4
MDMA

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

NCT03485287MDMA-assisted Therapy (100 to 125 mg)
Phase 2Posttraumatic Stress Disorder40%0/4100%4/40%0/4
Ketamine

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women

NCT04285684Ketamine During Lactation
EARLY_Phase 1Ketamine, Lactation40%0/40%0/40%0/4
Ketamine

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005CSF Capture Cohort 1
Phase 1Major Depressive Disorder40%0/4100%4/40%0/4
MDMA

Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00353938Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3)
Phase 2Posttraumatic Stress Disorder30%0/333%1/30%0/3
MDMA

Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

NCT00402298Full Dose (125 mg) MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder30%0/367%2/30%0/3
LSD

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

NCT00920387Full Dose LSD (200 mcg Stage 2)
Phase 2Anxiety30%0/3100%3/30%0/3
MDMA

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

NCT014583273,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Phase 2Posttraumatic Stress Disorder333%1/333%1/30%0/3
Ketamine

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

NCT01680172Ketamine
Phase 2Cancer, Depression30%0/3100%3/3not reported
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740Blinded Active Placebo MDMA-assisted Therapy (Stage 1)
Phase 2Posttraumatic Stress Disorder (PTSD)30%0/333%1/30%0/3
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740SRRs: Active Placebo
Phase 2Posttraumatic Stress Disorder (PTSD)30%0/3100%3/30%0/3
Ketamine

Ketamine for Depression Relapse Prevention Following ECT

NCT02414932Ketamine
EARLY_Phase 1Depression30%0/367%2/30%0/3
Ketamine

Ketamine for Depression Relapse Prevention Following ECT

NCT02414932Midazolam
EARLY_Phase 1Depression30%0/30%0/30%0/3
Ketamine

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186Follow-up Phase: Oral AD + Intranasal Placebo (2 Weeks)
Phase 3Depressive Disorder, Treatment-Resistant30%0/333%1/30%0/3
Ketamine

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

NCT02997722Ketamine Infusion
Phase 4Suicidal Ideation30%0/333%1/30%0/3
Ketamine

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

NCT05907213Ketamine (Ketalar) Dose Level 1
Phase 1Pain, Postoperative, Depression, Postpartum30%0/3100%3/30%0/3
Ketamine

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

NCT05907213Ketamine (Ketalar) Dose Level 2
Phase 1Pain, Postoperative, Depression, Postpartum30%0/3100%3/30%0/3
Ketamine

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

NCT05907213Ketamine (Ketalar) Dose Level 3
Phase 1Pain, Postoperative, Depression, Postpartum30%0/3100%3/30%0/3
Ketamine

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

NCT05907213Ketamine (Ketalar) Dose Level 4
Phase 1Pain, Postoperative, Depression, Postpartum30%0/3100%3/30%0/3
MDMA

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

NCT00252174Stage 1, Control
Phase 2Anxiety Disorder, Cancer20%0/20%0/20%0/2
MDMA

Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

NCT00402298Low Dose (25 mg) MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder20%0/2100%2/20%0/2
Ketamine

Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

NCT01309581Ketamine
NAMajor Depression, Bipolar Depression20%0/2100%2/2not reported
Ketamine

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

NCT01680172Placebo
Phase 2Cancer, Depression20%0/2100%2/2not reported
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740Lead In Open-Label: 125 mg MDMA-assisted Therapy
Phase 2Posttraumatic Stress Disorder (PTSD)20%0/2100%2/20%0/2
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740Open-Label Full Dose MDMA-assisted Therapy (125 mg) (Stage 2)
Phase 2Posttraumatic Stress Disorder (PTSD)20%0/2100%2/20%0/2
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT0168974012 Month Follow-Up: Open-Label Full Dose Lead-In
Phase 2Posttraumatic Stress Disorder (PTSD)20%0/20%0/20%0/2
MDMA

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT0168974012 Month Follow-Up: Active Placebo Dose
Phase 2Posttraumatic Stress Disorder (PTSD)20%0/20%0/30%0/2
Ketamine

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990Suicidal, Depression and Opioid Use With Ketamine
NADepression, Suicidal Ideation20%0/20%0/2not reported
Ketamine

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990Suicidal, Depression and Opioid With Saline
NADepression, Suicidal Ideation20%0/20%0/2not reported
MDMA

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

NCT01958593Placebo With Therapy (Stage 1)
Phase 2Posttraumatic Stress Disorder20%0/2100%2/20%0/2
MDMA

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

NCT01958593Placebo With Therapy (Stage 2)
Phase 2Posttraumatic Stress Disorder20%0/2100%2/20%0/2
MDMA

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

NCT01958593SRRs: Placebo With Therapy
Phase 2Posttraumatic Stress Disorder20%0/2100%2/20%0/2
Ketamine

RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

NCT03305055Fentanyl Plus Ketamine
Phase 4Acute Pain, Wound Care20%0/250%1/20%0/2
Ketamine

RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

NCT03305055Fentanyl Plus Saline
Phase 4Acute Pain, Wound Care20%0/250%1/20%0/2
Ketamine

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756Midazolam
Phase 2/Phase 3Major Depressive Disorder20%0/2100%2/20%0/2
Ketamine

Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers

NCT06001372Arm 1
EARLY_Phase 1Gastrointestinal Cancer, Depression250%1/250%1/20%0/2
Ketamine

Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

NCT01309581Methohexitol
NAMajor Depression, Bipolar Depression10%0/1100%1/1not reported
Ketamine

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958Placebo: Follow up Phase
Phase 2Treatment Resistant Depressive Disorder10%0/10%0/1not reported
Ketamine

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010Saline Followed by Lurasidone
Phase 2Bipolar Depression, Suicidal Ideas10%0/1100%1/10%0/1
Ketamine

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

NCT02997722Normal Saline Infusion
Phase 4Suicidal Ideation10%0/10%0/10%0/1
Ketamine

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756Ketamine
Phase 2/Phase 3Major Depressive Disorder10%0/1100%1/10%0/1
Ketamine

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

NCT04011592Ketamine 0.5 mg/kg
Phase 2Post Partum Depression10%0/1100%1/10%0/1
Ketamine

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

NCT04011592Ketamine 0.2 mg/kg
Phase 2Post Partum Depression10%0/1100%1/10%0/1
Ketamine

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

NCT04260607Experimental-Ketamine
Phase 3Suicide, Suicide Threat10%0/1100%1/10%0/1
Ketamine

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855OL Observation Period
Phase 4Depressive Disorder, Treatment-Resistant10%0/10%0/10%0/1
MDMA

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

NCT00252174Stage 1, Active
Phase 2Anxiety Disorder, Cancer0not reportednot reportednot reported
MDMA

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

NCT00252174Stage 2, Active
Phase 2Anxiety Disorder, Cancer0not reportednot reportednot reported
Ketamine

Treatment Study of Bipolar Depression

NCT00947791Ketamine/Midazolam
Phase 4Bipolar Disorder0not reportednot reportednot reported
Ketamine

Treatment Study of Bipolar Depression

NCT00947791Midazolam/Ketamine
Phase 4Bipolar Disorder0not reportednot reportednot reported
MDMA

Effects of MDMA on Emotional and Social Memories

NCT03050541Healthy Adult Volunteers-Placebo at Both Sessions
NAHealthy0not reportednot reportednot reported
Ketamine

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

NCT04260607Placebo-Saline
Phase 3Suicide, Suicide Threat0not reportednot reportednot reported

A project by Tyler Hathaway

Not a regulatory or clinical tool, and no medical advice. Not affiliated with any sponsor, regulator, or any organization whose trials appear here.

We use privacy-friendly, cookieless analytics to count visits and see which pages are read. No personal data is collected and nothing is sold or shared.